Rosuzet combination tablets for hypercholesterolemia and familial hypercholesterolemia (rosuvastatin calcium, ezetimibe, Ezalo, Roszet)

General information on Japanese Rosuzet combination tablets for hypercholesterolemia and familial hypercholesterolemia (rosuvastatin calcium, ezetimibe, Ezalo, Roszet)

Package details: 100 tablets

Manufacturer: Organon K. K., Japan

Active ingredients: rosuvastatin calcium (chemical formula (C22H27FN3O6S)2 Ca), ezetimibe (chemical formula C24H21F2NO3)

Medical effect: Rosuzet tablets are effective for the treatment of hypercholesterolemia and familial hypercholesterolemia.

Contraindications and precautions: do not use for pregnant, possibly pregnant or breastfeeding women. Do not use for patients with liver disorder or renal disorder.

If an allergic reaction occurs, stop using the medicine and consult with your doctor. If you’re taking any other medication or receiving any other treatment, you have to consult with your doctor before use.

Dosage and administration

For adults: take 1 tablet at a time, once a day, after a meal.

How effective are Rosuzet combination tablets from Japan for hypercholesterolemia and familial hypercholesterolemia (rosuvastatin calcium, ezetimibe, Ezalo, Roszet)?

Rosuzet combination tablets contain two active ingredients: rosuvastatin calcium, synthetic medicine of statin class, and ezetimibe, a cholesterol absorption and vegetal sterol inhibitor. These components provide the following effects:

• inhibiting production of cholesterol in the liver,
• blocking the absorption of cholesterol from the small intestine,
• stimulating the liver cells to absorb more cholesterol from blood circulation,
• consequently, lowering the cholesterol blood level.

Who should use Rosuzet combination tablets from Japan?

Rosuzet tablets are effective for the treatment of hypercholesterolemia and familial hypercholesterolemia. Studies showed that adding ezetimibe to the statin therapy allowed 71.5% patients of patients who didn’t reach the desired cholesterol level with statin monotherapy to get the desired reduction in LDL cholesterol levels (C. Gagne, H. E. Bays et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia // The American journal of cardiology. 2002, 90(10): 1084-91).